drugset

drugset / Trial / NCT01688024

Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis

NCT01688024 ↗

Phase 2 Unknown 130 enrolled Li, Zhiping, M.D. Johns Hopkins University · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of mitomycin C in the treatment of primary sclerosing cholangitis (PSC).

Timeline

Start: 2012-09
Primary completion: 2017-09
Completion: 2019-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mitomycin C	Other / unclassified	10 mg	—

Indications